dence or severity of acute GVHD and has the beneficial effect of accelerated engraftment as compared to the use of marrow alone, probably on the basis of an increased num-A 32-year-old male received an allogeneic peripheral blood stem cell transplant (alloPBSCT) for myelodysber of stem cells in the graft. Even though acute GVHD does not appear to be increased with alloPBSCT, we could plasia from his one HLA-A antigen mismatched brother. He is alive with trilineage engraftment and not be certain that the increased T cell content of the PBSC graft compared with marrow, might not effect immediate without active GVHD 200 days after transplant. In July 1986 he underwent orthotopic cardiac transplantation cardiac allograft rejection. Despite the immediate potential benefit over the use of bone marrow alone, there is anecfor viral cardiomyopathy and has received continuous immunosuppressive therapy. A post-transplant lymphodotal evidence for increased extensive chronic graft-versushost disease. The possible correlation with chronic organ proliferative disorder with Hodgkin-like histopathology was diagnosed in August 1993 and was successfully rejection is of concern. Overall, the potential for breaking tolerance for the transplanted solid organ and effecting its treated with four cycles of MOPP chemotherapy. Due to persistent pancytopenia he underwent a bone marrow rejection was of grave concern. We report successful allogeneic peripheral blood stem aspiration and biopsy in May 1996 which revealed monosomy 7 and morphologic changes compatible with cell transplantation for myelodysplasia secondary to chemotherapy for a Hodgkin-like post-transplant lymmyelodysplasia. This is the first report of a cardiac transplant recipient receiving an allogeneic hematopophoma in a recipient of a cardiac transplant. There was no evidence of cardiac graft rejection and engraftment was ietic stem cell transplant. Keywords: allogeneic; cardiac; stem cell; lymphoma; prompt and sustained. myelodysplasia; transplant
Myelodysplasia and secondary acute leukemia are well
A 23-year-old male underwent orthotopic cardiac transplandescribed complications of chemotherapy for malignant tation for a viral cardiomyopathy in July 1986. The postdisease. 1 Both have been successfully treated with allocardiac transplant course was complicated by mild rejection geneic bone marrow transplantation.
2,3 Post-transplant lymas demonstrated on multiple cardiac biopsies, and he phoma is an increasingly common complication among remained on cyclosporin A until FK506 was started prior solid organ transplant recipients and generally has a poor to alloPBSCT. The patient noted increasing adenopathy in outcome. 4 Recently, several reports of successful treatment May 1993 and biopsy of a right axillary lymph node in July with chemotherapy have appeared. 5, 6 As the number of 1993 revealed post-transplant lymphoproliferative disease. long-term survivors of solid organ transplantation
The lesion was characterized by a small population of increases, post-transplant lymphoma and other hematologReed-Sternberg-like cells that were positive for CD15, ical diseases amenable to allogeneic hematopoietic stem CD22 and CD30. They did not express CD45 and were cell transplantation are also likely to be seen more freadmixed with polyclonal populations of B and T cells. quently. Allogeneic peripheral blood stem cell transplan-EBER-1 and LMP staining were confined to the large tation has not been associated with an increase in the inci-CD30 + cell population. Although similar to Hodgkin's disease, this lesion could not be classified as such on formal review and has been reported previously in a liver trans-megaly on CT scan. After an initial therapeutic trial with Discussion interferon, without response, chemotherapy with MOPP Few cases of solid organ transplantation have been reported was started and continued to four cycles. Severe pancytoin hosts reconstituted with allogeneic hematopoiesis. The penia was noted with each treatment course requiring Gmajority of reported cases involve liver transplantation for CSF, and moderate thrombocytopenia persisted after end-stage liver disease due to either VOD or GVHD. [11] [12] [13] chemotherapy ceased. The patient was judged to be in comOnly one case of allogeneic bone marrow transplantation plete remission but a bone marrow aspirate and biopsy perhas been reported after solid organ transplantation.
14 formed in May 1994 was hypercellular with mild dysplastic Starzl et al 15 have postulated that donor passenger leukofeatures and a left shift. The patient was taking G-CSF at cytes in transplanted solid organs are capable of migrating that time which was thought to explain the marrow findfrom the organ and establishing micro-chimerism in the ings. A repeat marrow in May 1996 performed to evaluate recipient immune system. This micro-chimerism might be worsening thrombocytopenia, showed hypercellularity with crucial for recipient tolerance to the transplanted solid a left shift, dysplastic features and a blast count of 9%.
organ. Although initial reports of combined solid organ and Chromosome studies revealed monosomy 7.
bone marrow transplantation suggest enhanced graft surAfter thorough cardiac evaluation revealed acceptable vival, the degree of allogeneic reconstitution has been minicardiac function and HLA-typing identified a compatible mal. [16] [17] [18] Allogeneic hematopoietic reconstitution after brother (one HLA-A antigen mismatch; donor A1A2; myeloablative therapy however, replaces all components of recipient A1A11), he proceeded to transplant on an experithe host immune system. Thus, any micro-chimerism estabmental protocol (UPCI 95-064). This protocol aims to lished by passenger cells from the cardiac allograft prior to establish rapid engraftment and adequate acute GVHD conmyeloablative therapy would be destroyed. If this microtrol with FK506 alone, avoiding the engraftment delay chimerism is of importance for tolerance, then its ablation associated with methotrexate. 10 Busulfan 16 mg/kg orally might intensify the host-versus-graft reaction resulting in over 4 days, followed by cyclophosphamide 120 mg/kg i.v.
cardiac allograft rejection. Nonetheless, severe myelodysover 2 days (BuCy2) was given as conditioning. FK506 plasia is a uniformly rapidly fatal disorder that can only be was started on day −1 and has been continued since. No cured by allogeneic or syngeneic hematological reconstimethotrexate was given. His brother received G-CSF at 16 tution of the host. 2 Although there was diffuse erythema g/kg s.c. daily and underwent leukapheresis for the collecand atypical T lymphocytosis in the peripheral blood as tion of PBSC starting on the 4th day of G-CSF. Two 4-h early as day +7 after transplant, GVHD was not confirmed leukapheresis procedures, using bilateral antecubital fossa on skin biopsy. It is tantalizing to postulate that the lymphovenipuncture, were performed on consecutive days and cytosis was reactive against occult EBV+ post-transplant after processing, the product was transfused directly into lymphoma. Post-transplant lymphoma after allogeneic bone the patient. The total infused CD34 + cell count/kg was marrow transplantation has been successfully treated with 1.04 × 10 7 . The total cell count/kg and the mononuclear cell donor lymphocyte infusions, as has relapse after transplant count/kg in the apheresis product was 1.90 × 10 9 and for leukemia with the best results in chronic myelogenous 1.27 × 10 9 , respectively. The CFU-GM/kg was 5.79 × 10 5 , leukemia. 19, 20 The presence of a GVL effect is well docuthe BFU-E/kg was 2.46 × 10 6 and the CFU-GEMM/kg was mented with allogeneic bone marrow transplant. 21 /kg, respectively. and NK cells associated with the GVL effect. Given the An atypical lymphocytosis was detected in the peripheral dismal prognosis of post-transplant lymphoma not responblood starting on day +7 and by flow cytometry consisted sive to chemotherapy, or relapsing from complete mainly of a population of CD3 + CD5 + T cells. At the same remission, it would be reasonable to consider allogeneic time the patient's skin was noted to be diffusely erythema-PBSCT from a fully matched sibling. We suggest that solid tous with a purplish discoloration. He was treated with organ transplant recipients who develop myelodysplasia be methylprednisolone i.v. at 1 g per day for 3 days followed considered for allogeneic peripheral blood stem cell transby 2 mg/kg of prednisone equivalent i.v. on suspicion of plantation as curative therapy. This initial experience shows hyperacute GVHD and possible cardiac graft rejection. A that immediate organ rejection is not an obligatory outcome skin biopsy performed on day +8 did not reveal GVHD and associated with the procedure. steroids were tapered to 1 mg/kg of prednisone equivalent. Engraftment was prompt and sustained with neutrophils Ͼ500/l on day +15 and platelets Ͼ50 000/l on day +13.
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